Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (810)	1/22/2000 5:12:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3158

<<This would place ex-Genetics Institute management, now largely heading Wyeth, with significant influence over the direction of research at REGN? Would be a definite plus in terms of guidance/prioritization, but I can't imagine it being construed as an overall positive.>> Hard to say, but I am one who believe that it will be more than overall positive for REGN. REGN needs experience and help in preclinical/clinical field, as well in small molecules programs. White-WL have this. Also, have in mind that for bt (at 460 mm cap) in broad 50-50 deal with largest (however, at this point I think that PFE will be one who will own WL) pharma (at 300 bb cap) is a challenge, at the least. Miljenko

To: scaram(o)uche who wrote (810)	1/22/2000 5:15:00 PM
From: aknahow	Respond to of 3158

One further thought, if P & G does take them over, this merger should create a larger move of capital out of the merged entity than is common with many mergers. Some long term holders of P & G will not like the merger and get out. These funds are unlikely to move to either the drug or biotech industry but some of the AHP & WLA long termers will also sell out and a good portion of these funds will move back into the "drug" sector. Can't quantify any of this but believe the reinvestment flow will be greater than if PFE picks up WLA. (on a relative basis, adjusting for non inclusion of AHP in WLA/PFE deal). While I can't quantify any of this, I can speculate on the concept. If just 10% of the previous holders of AHP/WLA sell out and just 20% of the proceeds go back into "drugs" one is looking at about $2.5 to $3.5 billion going into the drug and pharmaceutical and biotech stocks.